A Covid-19 drug manufactured by Kerala-based organization, PNB Vesper, has received nod by DCGI to conduct Phase 3 clinical trials. The organization will be conducting a nationwide multi-centred clinical trial of the drug- PNB-001 (GPP-BALACOVIN), on Covid-19 patients who are hospitalised and are on oxygen help. The trial is anticipated to be carried out amongst a huge patient population in more than 12 hospitals across India.
The organization has claimed that the drug, GPP- BALACOVIN is secure to use and has considerable efficacy when it comes to saving the Covid-19 hospitalised patients with oxygen help. According to PN Balaram, CEO, PNB Vesper Life Sciences mentioned, the drug can be promising for COVID-19 patients across the world. He explained that it is “explicitly non-toxic to humans” as shown in the initial two phases of human clinical trials. “After the treatment with the drug, none of the patients reported any post-treatment health risks,” mentioned Balaram.
It is to note that there are 28 post-covid lengthy-term complications that the WHO has identified. And the outcomes of clinical trials have shown that patients who have been administered the Covid-19 drug did not have any lengthy-term overall health threat when compared to these who received normal remedy, PNB Vesper mentioned in a press note. Dr Eric Lattman, Vice President, PNB Vesper highlighted that the overall performance of the drug is a great deal superior more than the existing remedy paradigm.
To be sure, in Covid-19 situations, patients are ordinarily at threat with obtaining back fungus infection mainly because of immunosuppressants and if immunosuppressants are not monitored, patients can have an aggressive inflammatory response- cytokine storm. The organization mentioned that the drug has been modulated in a way that can act as a strong anti-inflammatory agent with immuno modulation properties.
It was discovered that the turbo anti-inflammatory molecule along with immuno-modulation properties can be really valuable in the remedy of numerous acute inflammatory and auto-immune ailments along with cancer remedies as nicely in the future, added Dr Lattman.
Meanwhile, the outcomes of the initial two phases of clinical trials have been published in a pre-journal by British Medical Journal(BMJ) and Yale university.